In a groundbreaking review set to reshape public health policies, researchers at the University of Mississippi have presented compelling evidence that ambient air pollution levels deemed safe by current Environmental Protection Agency (EPA) standards may nonetheless pose a significant risk to cardiovascular health. This extensive review, recently published in the scientific journal Environmental Pollution, synthesizes decades of global research, underscoring the urgent need to revisit and potentially lower regulatory thresholds for fine particulate matter, specifically PM2.5.

PM2.5 refers to microscopic particulate matter with a diameter less than 2.5 microns—around 20 times smaller than a human hair—which makes them capable of penetrating deep into the respiratory tract and entering the bloodstream. These particles originate from diverse sources such as vehicular emissions, industrial manufacturing, biomass burning, and dust from agricultural activities. Their diminutive size allows them to circumvent the body’s natural defense mechanisms, reaching vital organs and triggering systemic health effects.

The review meticulously analyzed 95 peer-reviewed studies that addressed cardiovascular impacts related to low-level PM2.5 exposures worldwide. Strikingly, approximately two-thirds of these studies demonstrated significant associations between PM2.5 exposure and adverse cardiovascular outcomes, including heart attacks, strokes, and increased arterial plaque accumulation. Such findings suggest that even concentrations below the EPA’s current allowable limits can compromise cardiovascular function and contribute to disease progression.

One of the most alarming revelations from the review is the heightened vulnerability of specific demographic groups. Older adults, infants, individuals with preexisting heart conditions, socioeconomically disadvantaged communities, and marginalized populations bear a disproportionate burden of the health consequences posed by low-level PM2.5 exposure. The underlying reasons include a combination of biological susceptibility, existing comorbidities, and environmental inequities that result in unequal pollution exposures.

Experts leading the study emphasize that the source of PM2.5 plays a pivotal role in its health impact. Traffic-related pollution, industrial emissions, and rural dust each possess unique chemical compositions and particle characteristics that influence toxicity. For instance, black carbon—a key component of soot prevalent in urban areas—has been linked to respiratory and cardiovascular morbidity. Understanding these nuances is critical for tailoring regulatory actions and mitigation strategies.

Technological advances in air quality monitoring have highlighted the dynamic nature of pollution exposure. Daily fluctuations in PM2.5 concentrations, even within previously considered ‘safe’ ranges, can exacerbate risk. The lack of widespread public awareness regarding these subtleties hampers proactive health protection. Consequently, researchers call for enhanced education campaigns to inform communities about real-time air quality risks and personal protection measures.

Cardiovascular disease remains the leading cause of mortality on a global scale, and these findings carry profound implications for public health. The pathophysiological mechanisms implicate PM2.5 in accelerating atherosclerosis, fostering systemic inflammation, and enhancing thrombogenic potential. These processes collectively escalate the likelihood of acute cardiovascular events. The pervasiveness of PM2.5 exposure across urban, industrial, and rural environments necessitates a broad-reaching response.

Current public health recommendations to mitigate individual risk include monitoring localized air quality indices and adopting practical interventions on high-exposure days. Utilization of high-efficiency particulate air (HEPA) filtration systems within indoor environments, combined with the use of adequately rated masks such as N95 respirators, can substantially reduce personal particulate inhalation. These tools are particularly vital for sensitive populations engaging in outdoor activities during episodes of elevated pollution.

The review underscores the critical interplay between environmental science and clinical health disciplines. Healthcare providers are encouraged to integrate pollution exposure assessments into routine cardiovascular risk evaluations. Furthermore, temporal spikes in air pollution should prompt heightened clinical vigilance among patients with known cardiovascular vulnerabilities.

While treatment modalities for pollution-induced cardiovascular damage remain limited, prevention through regulatory intervention and public engagement is paramount. This study advocates for policy reforms that reflect emerging scientific evidence—ideally, lowering the maximum allowable PM2.5 levels to afford more comprehensive protection for population health. Robust air quality enforcement accompanied by community education initiatives constitutes the frontline defense.

Mississippi’s unique environmental landscape, marked by a blend of rural, industrial, and urban pollution sources, exemplifies the broader challenges in managing fine particulate exposure. Researchers at the University of Mississippi have specifically documented elevated black carbon concentrations across various locations within the state, correlating these findings with increased respiratory admissions. Such regional data, when synthesized with global research, bolster the call for targeted policy improvements.

This collective body of work spotlights the critical need for multi-sectoral collaboration spanning environmental regulation, healthcare, urban planning, and public advocacy. Addressing the insidious cardiovascular risks posed by low-level PM2.5 pollution demands concerted efforts to enhance air quality monitoring infrastructure, refine healthcare response frameworks, and cultivate informed, empowered communities.

Ultimately, the path forward rests on reimagining air quality standards rooted in rigorous health evidence. By recognizing and acting upon the risks associated with fine particulate pollution at even low concentrations, society can better safeguard cardiovascular health and reduce the burden of pollution-related morbidity on a global scale.

---

Subject of Research: Health impacts of low-level ambient fine particulate matter (PM2.5) exposure and cardiovascular outcomes

Article Title: A systematic review of low-level ambient fine particulate matter (PM2.5) exposures and adverse cardiovascular health outcomes

Web References:

• EPA Air Quality Basics: https://www.epa.gov/pm-pollution/particulate-matter-pm-basics
• EPA Air Pollution and Cardiovascular Disease: https://www.epa.gov/air-research/air-pollution-and-cardiovascular-disease-basics
• WHO Cardiovascular Diseases Overview: https://www.who.int/health-topics/cardiovascular-diseases#tab=tab_1

References:
University of Mississippi Review in Environmental Pollution, DOI: 10.1016/j.envpol.2026.127978

Image Credits: Photo illustration by John McCustion/University Marketing and Communications

Keywords: Air pollution, PM2.5, cardiovascular health, fine particulate matter, environmental toxicology, public health, pollution regulation, black carbon, respiratory health, environmental epidemiology, pollution exposure, air quality monitoring

Google has applied for an experimental mosquito release permit to deploy millions of non-biting southern house mosquitoes that it has infected with the bacterium Wolbachia pipientis, in an effort to reduce mosquito-borne diseases like West Nile virus.

Google has applied for an experimental mosquito release permit to deploy millions of non-biting southern house mosquitoes that it has infected with the bacterium Wolbachia pipientis, in an effort to reduce mosquito-borne diseases like West Nile virus.

Google has applied for an experimental mosquito release permit to deploy millions of non-biting southern house mosquitoes that it has infected with the bacterium Wolbachia pipientis, in an effort to reduce mosquito-borne diseases like West Nile virus.

Cardiovascular disease remains the world’s biggest killer, responsible for millions of deaths every year. Most heart attacks and strokes can be traced back to a slow-moving process that begins decades before symptoms appear. This process, known as atherosclerosis, causes fatty deposits to build up inside arteries, gradually reducing blood flow and increasing the risk of […]

The post New Way to Control Dangerous Artery Plaques in Heart Disease appeared first on Knowridge Science Report.

For many families, Alzheimer’s disease begins with small changes that are easy to overlook. A person may forget appointments, struggle to find the right words, or become confused about familiar tasks. Over time, these symptoms often worsen as the disease gradually damages the brain. Because Alzheimer’s develops slowly, doctors have long searched for ways to […]

The post A New Blood Test May Spot Alzheimer’s Earlier and More Easily appeared first on Knowridge Science Report.

In a groundbreaking advancement at the intersection of neurology and ophthalmology, researchers have unveiled an innovative, non-invasive approach for early diagnosis of Parkinson’s disease (PD) by detecting retinal biomarkers. This novel technique leverages electroretinography (ERG) and pupillometry to identify subtle retinal changes in MPTP-treated monkeys—animals that serve as a reliable model for human Parkinson’s disease. The work, led by a multidisciplinary team including Munro, Lavigne, and Fecteau, and detailed in a recent publication in npj Parkinson’s Disease, promises to revolutionize how clinicians approach the detection and monitoring of this complex neurodegenerative disorder.

Parkinson’s disease is characterized by the progressive degeneration of dopaminergic neurons in the brain, notably affecting motor function and leading to tremors, rigidity, and bradykinesia. Historically, diagnosis has been primarily clinical, based upon observable motor symptoms which often appear after significant neurodegeneration has already occurred. This delayed diagnosis limits treatment effectiveness during critical early stages. Therefore, the identification of accessible, objective biomarkers is crucial, and retinal health has emerged as a promising candidate due to its neural composition and direct connectivity to the brain.

The retina is a neural tissue extension of the central nervous system, possessing dopaminergic amacrine cells whose dysfunction reflects Parkinsonian neurodegeneration. ERG measures the electrical response of various retinal cells to light stimuli, providing exceptional resolution of retinal function. In conjunction, pupillometry analyzes the dynamics of pupil size and reactivity, which mirror autonomic nervous system integrity impaired in PD. Together, these modalities offer a window into the neurochemical and functional state of the retina, which may parallel brain pathology in Parkinson’s.

The experimental framework employed MPTP (1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine), a neurotoxin used to induce Parkinsonism in non-human primates by selectively targeting dopaminergic neurons. This model mimics human PD both behaviorally and neurologically, making it ideal for investigating subtle physiological changes that occur before overt motor symptoms. By analyzing ERG signals and pupillometric data longitudinally, the study demonstrated that early retinal dysfunction is detectable prior to full clinical manifestation, a finding with profound diagnostic implications.

One of the most compelling technical findings pertains to alterations in the ERG waveform components—specifically the a-wave and b-wave amplitudes and latencies—which reflect photoreceptor and bipolar cell function, respectively. The researchers observed a consistent diminution in b-wave amplitude correlating with disease progression, signifying inner retinal dysfunction associated with dopaminergic depletion. These electrophysiological signatures provide objective, quantifiable metrics that can be tracked over time with standard ERG equipment.

Pupillometry further augmented these insights by revealing attenuated pupil constriction responses to direct light stimuli and slower reflex recovery times in MPTP monkeys compared to healthy controls. These deviations are indicative of autonomic dysregulation and impaired retinal ganglion cell activity — both hallmarks of PD pathology. The synergy between electrophysiological and pupillary measurements enhances diagnostic accuracy by capturing complementary aspects of retinal impairment.

What makes this approach especially exciting is its potential for translation into clinical practice. ERG and pupillometry are already established diagnostic tools in ophthalmology, broadly available, non-invasive, and well tolerated by patients. The adaptation of these methods for PD screening requires only calibration to recognize specific retinal biomarker patterns identified in this study. Such an innovation could facilitate diagnostic screening in outpatient clinics and even enable at-home monitoring via portable, user-friendly devices.

Moreover, the technique holds promise for monitoring disease progression and assessing therapeutic efficacy. Since retinal changes appear dynamically correlated with nigrostriatal neuron loss, repeated ERG and pupillometric assessments could provide a surrogate biomarker for neuronal status, empowering neurologists to tailor treatment regimens based on real-time physiological data. This could herald a paradigm shift from symptom-driven approaches to biomarker-guided precision medicine in Parkinson’s care.

The integration of machine learning algorithms was an ingenious aspect of the analysis pipeline. By feeding raw electrophysiological and pupillometric datasets into advanced pattern recognition models, the research team enhanced sensitivity and specificity, enabling discrimination even in early-stage disease states. This fusion of artificial intelligence with retinal biometrics exemplifies the future direction of neurodegenerative disease diagnostics—highly data-driven, minimally invasive, and scalable.

Importantly, this research also underscores the retina’s emerging status as a biomarker-rich neuroanatomical structure. Beyond Parkinson’s, retinal imaging and electrophysiology may aid in detection of other neurodegenerative disorders such as Alzheimer’s disease, multiple sclerosis, and Huntington’s disease. As imaging resolution and analytical techniques improve, the retina may serve as a readily accessible portal for brain health diagnostics, accessible even to resource-limited settings.

Despite its enormous potential, transitioning from primate studies to human clinical application requires rigorous validation. Variability in human retinal physiology, comorbid ocular conditions, and environmental factors must be meticulously accounted for in subsequent trials. Longitudinal studies with diverse patient cohorts will be necessary to establish normative datasets and refine biomarker thresholds. Regulatory approval pathways will also need to address device calibration and reproducibility challenges.

Ethical dimensions emerge as well—the prospect of early detection of neurodegenerative disease prior to symptom onset raises questions about patient counseling, psychological impacts, and healthcare resource allocation. Nevertheless, the overarching benefits of preserving neurological function and extending quality of life argue strongly for continued investment in this research trajectory.

In conclusion, the pioneering work by Munro, Lavigne, Fecteau, and colleagues sets the stage for a new frontier in Parkinson’s disease diagnostics based on non-invasive retinal biomarker detection. Through sophisticated use of ERG and pupillometry in an established animal model, the study elucidates measurable retinal changes corresponding to dopaminergic neurodegeneration. The implications span early diagnosis, disease monitoring, and potentially new therapeutic endpoints, offering hope to millions affected by this debilitating disorder. As clinical translation unfolds, this approach may become a cornerstone of personalized neurology, harnessing the eye as a window to the brain’s health in an unprecedented way.

---

Subject of Research: Parkinson’s disease diagnosis using retinal biomarkers detected by electroretinography (ERG) and pupillometry in MPTP monkeys

Article Title: Improving Parkinson’s disease diagnosis by non-invasive detection of retinal biomarkers in MPTP monkeys using ERG and pupillometry

Article References:
Munro, J., Lavigne, AA., Fecteau, S. et al. Improving Parkinson’s disease diagnosis by non-invasive detection of retinal biomarkers in MPTP monkeys using ERG and pupillometry. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01391-y

Image Credits: AI Generated

In a groundbreaking study published in npj Parkinson’s Disease, researchers led by Bu, Pang, Li, and colleagues have unveiled intricate links between the functional disturbances in the thalamus—a critical relay center within the brain—and the genetic underpinnings of varying motor subtypes in Parkinson’s disease (PD). This comprehensive investigation illuminates the complex neurogenetic landscape underlying PD and offers promising avenues for tailored therapeutic strategies, marking a significant leap forward in our understanding of this debilitating neurodegenerative disorder.

The thalamus, often described as the brain’s gateway to the cortex, plays a pivotal role in integrating and transmitting motor and sensory signals. Dysfunction within this region has long been suspected in Parkinson’s pathology; however, the precise ways in which thalamic organization varies across PD motor subtypes remained elusive until now. The research team employed advanced neuroimaging techniques alongside cutting-edge genetic analyses to map functional disturbances within the thalamic nuclei and correlate these with specific genetic architectures characterizing tremor-dominant, akinetic-rigid, and mixed motor phenotypes.

Leveraging resting-state functional MRI (rs-fMRI), the study meticulously charted the connectivity patterns of thalamic subregions in a well-characterized cohort of PD patients. The imaging data revealed discrete, subtype-specific disruptions in thalamic connectivity. Notably, individuals exhibiting tremor-dominant PD presented with alterations predominantly in motor relay nuclei associated with sensorimotor integration, whereas those with akinetic-rigid features showed more widespread thalamocortical disconnection implicating premotor and supplementary motor areas. These observations confirm the thalamus’s heterogeneous involvement in PD and underscore its contributory role in defining motor symptomatology.

Complementing the neuroimaging insights, the genetic dimension of the study unveiled unique gene-expression profiles linked to the observed thalamic disturbances. Utilizing whole-genome sequencing combined with transcriptomic analyses, the authors identified differential expression of genes implicated in synaptic plasticity, dopaminergic signaling, and neuroinflammatory pathways. These genetic signatures not only align with known PD risk loci but also highlight novel candidates potentially driving the functional reorganization of thalamic circuits observed in distinct motor subtypes.

Critically, the research elucidates the bidirectional interplay between genetic predisposition and neural network dysfunction. The data suggest that specific genetic variants may predispose certain thalamic nuclei to maladaptive plasticity or neuron loss, thereby sculpting the motor phenotype expressed by the individual. This nuanced understanding challenges the one-size-fits-all model of Parkinson’s disease, advocating instead for a precision medicine approach tailored to the molecular and functional profile of each patient.

Beyond mechanistic insights, the study carries profound implications for biomarker development and clinical management. Thalamic connectivity patterns identified through non-invasive imaging could serve as reliable proxies for underlying genetic risk, facilitating early diagnosis and subtype differentiation. Moreover, these biomarkers offer a robust framework for monitoring disease progression and therapeutic efficacy, especially as novel gene-targeted and circuit-specific interventions emerge.

The authors also discussed the implications of their findings in the context of current therapeutic paradigms. Deep brain stimulation (DBS), a well-established treatment primarily targeting subthalamic and globus pallidus regions, may benefit from refined targeting strategies informed by thalamic functional disturbances. Tailoring stimulation parameters to modulate aberrant thalamocortical circuits could enhance symptomatic relief and potentially slow disease progression in select patient subgroups.

Importantly, this study paves the way for future exploration into non-motor symptoms of PD, many of which are linked to thalamic and cortical network dysfunction. Cognitive impairment, mood disorders, and sleep disturbances, often co-occurring in PD, may similarly originate from genetically mediated disruptions in thalamic circuits. Comprehensive phenotyping linked with multimodal imaging and genomics promises to unravel these complex associations, enhancing holistic patient care.

The methodological rigor of the investigation deserves emphasis as well. The integration of multimodal datasets—combining neuroimaging, genomic sequencing, and clinical phenotyping—exemplifies the power of interdisciplinary approaches in contemporary neuroscience. Such synergy not only refines causal inferences but also optimizes the translational potential of findings from bench to bedside.

Furthermore, the study’s large, demographically diverse cohort strengthens the generalizability of its conclusions across populations, addressing a persistent gap in PD research that often suffers from limited ethnic and genetic representation. This inclusivity underscores the relevance of the findings on a global scale and encourages equitable development of new diagnostic and treatment modalities.

While the discoveries presented are monumental, the authors carefully acknowledge limitations inherent to their work. The cross-sectional design precludes definitive conclusions about causality, and longitudinal studies are warranted to track how thalamic and genetic abnormalities evolve over disease progression. Additionally, expanding research to include prodromal and preclinical PD stages may elucidate early pathophysiological mechanisms amenable to intervention.

In conclusion, this study by Bu et al. represents a watershed moment in Parkinson’s disease research, intricately linking thalamic functional disruptions with distinct genetic profiles across motor subtypes. This paradigm-shifting work offers a blueprint for personalized neurology, integrating neuroimaging and genetic data to dissect disease heterogeneity. As the field advances towards precision medicine, such insights will be instrumental in transforming the care landscape for millions affected by Parkinson’s worldwide.

With these revelations, the quest continues to harness burgeoning neurotechnological and genomic tools to decode PD’s enigmatic nature further. Understanding the thalamus’s role as both a nexus and a battleground in this disease could unlock new frontiers, ultimately yielding more effective and individualized therapies that halt or even reverse the debilitating march of Parkinson’s.

---

Subject of Research: Functional organization of the thalamus and its genetic correlates in motor subtypes of Parkinson’s disease

Article Title: Correlation of thalamic functional organization disturbances and genetic architecture in motor subtypes of Parkinson’s disease

Article References:
Bu, S., Pang, H., Li, X. et al. Correlation of thalamic functional organization disturbances and genetic architecture in motor subtypes of Parkinson’s disease. npj Parkinsons Dis. (2026). https://doi.org/10.1038/s41531-026-01417-5

Image Credits: AI Generated

In a groundbreaking study set to reshape our understanding of metabolic diseases, researchers have uncovered a pivotal mechanism linking the impaired differentiation of adipocytes in visceral fat to the pathogenesis of metabolic dysfunction-associated steatotic liver disease (MASLD). This discovery, meticulously detailed in a forthcoming publication in Nature Communications, delivers fresh insights into the cellular dynamics that precipitate one of the most pressing health crises of the 21st century.

Metabolic dysfunction-associated steatotic liver disease, previously known by its more controversial name, non-alcoholic fatty liver disease (NAFLD), represents a spectrum of liver conditions marked by excessive fat accumulation in liver cells. This condition can progress to more severe stages, such as steatohepatitis, fibrosis, cirrhosis, and ultimately liver failure or hepatocellular carcinoma. Despite extensive research, the precise cellular and molecular contributors to its onset and progression remain incompletely understood, impeding the development of effective therapeutic strategies.

Central to this new investigation is the role of adipocytes — the fat-storing cells within adipose tissue — particularly those residing in visceral fat depots. Visceral adipose tissue, distinct from subcutaneous fat, envelopes internal organs and is metabolically active, influencing systemic inflammation and insulin resistance. The study reveals that the degree to which preadipocytes differentiate into mature, functional adipocytes within visceral fat drastically influences metabolic homeostasis and liver health.

Employing state-of-the-art single-cell RNA sequencing, combined with sophisticated lineage tracing techniques, the researchers delineated the molecular signature of adipocyte populations in human visceral fat samples. They identified a marked reduction in the differentiation capacity of progenitor cells into mature adipocytes in individuals exhibiting MASLD. This deficit in differentiation results in a dysfunctional adipose tissue microenvironment, characterized by impaired lipid storage and elevated inflammatory signaling, both of which contribute to metabolic derangements.

The mechanistic underpinnings were further elucidated through in vivo models, where genetically engineered mice with selectively impaired adipocyte differentiation in visceral fat recapitulated key features of MASLD, including hepatic steatosis and inflammation. Notably, these models highlight the crosstalk between dysfunctional adipose tissue and the liver, mediated by altered adipokine profiles and increased free fatty acid flux, reinforcing the concept that visceral fat health is intimately tied to liver disease progression.

Moreover, the work unambiguously documents the disruption of key transcriptional regulators essential for adipocyte maturation, such as PPARγ and C/EBPα, within defective visceral fat depots. This transcriptional dysregulation appears to be a linchpin of the pathological cascade, suggesting that therapeutic modulation of these pathways might restore adipocyte differentiation capacity and ameliorate metabolic dysfunction.

The inflammatory milieu generated by poorly differentiated adipocytes also plays a salient role in disease manifestation. Elevated secretion of proinflammatory cytokines, including TNF-α and IL-6, promotes systemic low-grade inflammation, a recognized driver of insulin resistance and hepatic injury. Thus, the study delineates a vicious cycle wherein impaired adipocyte maturation exacerbates inflammation, which in turn further inhibits differentiation processes, compounding metabolic impairment.

From a clinical perspective, these findings carry significant implications. The assessment of adipocyte differentiation status within visceral fat may emerge as an innovative biomarker for early MASLD risk stratification. Furthermore, interventions aimed at enhancing adipogenesis or counteracting adipose tissue inflammation could constitute novel therapeutic avenues to halt or reverse disease progression, potentially transforming patient outcomes.

This research also challenges the prevailing notion that mere adiposity is the primary determinant of metabolic risk. Instead, it posits that qualitative changes within adipose tissue, specifically differentiation defects, are critical determinants of metabolic health, inviting a paradigm shift in how obesity-related complications are conceptualized and managed.

Intriguingly, the study advocates for a refined focus on cell-specific therapies that reinvigorate the adipogenic program, possibly through pharmacologic agents targeting the implicated transcription factors or signaling pathways. This approach could offer a more precise treatment modality, contrasting with the often blunt instrument of systemic metabolic control.

In parallel, the research underscores the importance of early detection of adipose tissue dysfunction. Non-invasive imaging modalities or circulating biomarkers reflecting adipocyte differentiation status could facilitate prompt clinical intervention, mitigating liver damage before irreversible fibrosis ensues.

While the research is pioneering, certain questions remain open for future exploration. For instance, the interplay between genetic predisposition, environmental factors such as diet and physical activity, and their collective impact on adipocyte differentiation warrants further inquiry. Additionally, longitudinal studies are needed to validate whether restoring adipocyte differentiation can directly translate into clinical remission of MASLD.

In summary, this seminal work inaugurates a new chapter in metabolic disease biology by linking diminished adipocyte differentiation in visceral fat with the complex etiopathogenesis of metabolic dysfunction-associated steatotic liver disease. Its implications resonate across fundamental science and clinical practice, heralding prospects for innovative diagnostics and personalized therapeutics that may stem the burgeoning tide of liver-related metabolic disorders.

Researchers and clinicians alike are poised to benefit from these insights, which illuminate the nuanced cellular landscapes underlying MASLD and spotlight a hitherto underappreciated target: the adipocyte differentiation machinery. As this field advances, the hope is to translate these molecular discoveries into tangible health benefits for millions at risk worldwide.

---

Subject of Research:
Metabolic dysfunction-associated steatotic liver disease and the cellular mechanisms of adipocyte differentiation in visceral adipose tissue.

Article Title:
Decreased degree of adipocyte differentiation in visceral adipose tissue contributes to metabolic dysfunction-associated steatotic liver disease.

Article References:
Gelev, K.Z., Lee, S.H.T., Alvarez, M. et al. Decreased degree of adipocyte differentiation in visceral adipose tissue contributes to metabolic dysfunction-associated steatotic liver disease. Nat Commun (2026). https://doi.org/10.1038/s41467-026-73660-6

Image Credits:
AI Generated

Surviving a heart attack is often only the beginning of a long recovery journey. While doctors focus heavily on repairing the damage to the heart, many patients notice unexpected changes in the months and years that follow. Some experience anxiety, depression, forgetfulness, poor concentration, or other difficulties involving memory and thinking. For decades, scientists have […]

The post Why Heart Attack Survivors Struggle with Memory and Mood appeared first on Knowridge Science Report.

Many people have tried brain-training games and apps that promise to improve memory, sharpen attention, and keep the mind healthy as we age. These programs have become increasingly popular, especially among older adults who want to maintain their mental abilities. However, one important question has remained unanswered for years: do the benefits stay limited to […]

The post Brain Training Apps Provide Surprising Benefits to Older People appeared first on Knowridge Science Report.